WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NBIX

Based on 15 analysts offering 12 month price targets for Neurocrine Biosciences Inc

Min Forecast
$141.00-7.72%
Avg Forecast
$179.33+17.36%
Max Forecast
$203.00+32.85%

Should I buy or sell NBIX stock?

Based on 15 analysts offering ratings for Neurocrine Biosciences Inc.

Strong Buy
Strong Buy
11 analysts 73.33%
Buy
3 analysts 20%
Hold
1 analysts 6.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their NBIX stock forecasts and price targets.

NBIX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-12
lockedlocked$00.00+00.00%2025-12-11
lockedlocked$00.00+00.00%2025-12-08
lockedlocked$00.00+00.00%2025-12-05Find Out Why
lockedlocked$00.00+00.00%2025-11-11
JP Morgan
Top 4%
97
Strong BuyMaintains$179.00+17.15%2025-11-03
Truist Securities
Top 14%
87
Strong BuyReiterates$172.00+12.57%2025-10-30
Canaccord Genuity
Top 46%
55
Strong BuyMaintains$164.00+7.33%2025-10-29
Citigroup
Top 8%
93
Strong BuyMaintains$203.00+32.85%2025-10-29Find out why
Piper Sandler
Top 5%
96
Strong BuyMaintains$179.00+17.15%2025-10-29Find out why

1 of 2

Forecast return on equity

Is NBIX forecast to generate an efficient return?

Company
45.93%
Industry
284.81%
Market
228.08%
NBIX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NBIX forecast to generate an efficient return on assets?

Company
32.34%
Industry
156.72%
NBIX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NBIX earnings per share forecast

What is NBIX's earnings per share in the next 3 years based on estimates from 30 analysts?

Avg 1 year Forecast
$5.14+19.24%
Avg 2 year Forecast
$6.89+59.8%
Avg 3 year Forecast
$8.45+96.12%
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NBIX revenue forecast

What is NBIX's revenue in the next 3 years based on estimates from 31 analysts?

Avg 1 year Forecast
$2.9B+8.66%
Avg 2 year Forecast
$3.4B+28.23%
Avg 3 year Forecast
$3.7B+39.56%
NBIX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NBIX earnings growth forecast

How is NBIX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
25.34%
Industry
364.79%
Market
42.65%
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NBIX revenue growth forecast

How is NBIX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
12.18%
Industry
132.41%
Market
25.62%
NBIX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NBIX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NBIX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
NBIX$152.80$179.33+17.36%Strong Buy
VTRS$11.65$15.00+28.76%Strong Buy
RDY$14.02N/AN/A
ELAN$21.29$23.86+12.06%Strong Buy
RGC$16.60N/AN/A
View Top Pharmaceutical Stocks

Neurocrine Biosciences Stock Forecast FAQ

Is Neurocrine Biosciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NASDAQ: NBIX) stock is to Strong Buy NBIX stock.

Out of 15 analysts, 11 (73.33%) are recommending NBIX as a Strong Buy, 3 (20%) are recommending NBIX as a Buy, 1 (6.67%) are recommending NBIX as a Hold, 0 (0%) are recommending NBIX as a Sell, and 0 (0%) are recommending NBIX as a Strong Sell.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

What is NBIX's earnings growth forecast for 2025-2027?

(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual earnings growth rate of 25.34% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 364.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.

Neurocrine Biosciences's earnings in 2025 is $428,000,000.On average, 30 Wall Street analysts forecast NBIX's earnings for 2025 to be $512,397,553, with the lowest NBIX earnings forecast at $444,587,707, and the highest NBIX earnings forecast at $579,988,045. On average, 29 Wall Street analysts forecast NBIX's earnings for 2026 to be $686,693,083, with the lowest NBIX earnings forecast at $353,715,934, and the highest NBIX earnings forecast at $942,218,846.

In 2027, NBIX is forecast to generate $842,772,383 in earnings, with the lowest earnings forecast at $451,427,518 and the highest earnings forecast at $1,521,159,982.

What is NBIX's revenue growth forecast for 2025-2027?

(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 12.18% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.

Neurocrine Biosciences's revenue in 2025 is $2,682,700,000.On average, 31 Wall Street analysts forecast NBIX's revenue for 2025 to be $290,642,109,670, with the lowest NBIX revenue forecast at $275,088,020,782, and the highest NBIX revenue forecast at $302,008,559,242. On average, 30 Wall Street analysts forecast NBIX's revenue for 2026 to be $342,987,601,120, with the lowest NBIX revenue forecast at $303,504,144,712, and the highest NBIX revenue forecast at $382,072,234,736.

In 2027, NBIX is forecast to generate $373,298,133,312 in revenue, with the lowest revenue forecast at $295,029,160,382 and the highest revenue forecast at $451,567,106,242.

What is NBIX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NBIX) forecast ROA is 32.34%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 156.72%.

What is NBIX's Price Target?

According to 15 Wall Street analysts that have issued a 1 year NBIX price target, the average NBIX price target is $179.33, with the highest NBIX stock price forecast at $203.00 and the lowest NBIX stock price forecast at $141.00.

On average, Wall Street analysts predict that Neurocrine Biosciences's share price could reach $179.33 by Dec 12, 2026. The average Neurocrine Biosciences stock price prediction forecasts a potential upside of 17.36% from the current NBIX share price of $152.80.

What is NBIX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NBIX) Neurocrine Biosciences's current Earnings Per Share (EPS) is $4.31. On average, analysts forecast that NBIX's EPS will be $5.14 for 2025, with the lowest EPS forecast at $4.46, and the highest EPS forecast at $5.82. On average, analysts forecast that NBIX's EPS will be $6.89 for 2026, with the lowest EPS forecast at $3.55, and the highest EPS forecast at $9.45. In 2027, NBIX's EPS is forecast to hit $8.45 (min: $4.53, max: $15.26).

What is NBIX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NBIX) forecast ROE is 45.93%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.